Estuary Biotherapeutics has swum out of stealth with $103 million in funding to power a pair of gene therapies into clinical ...

Two new biotechnology majors have been introduced by QUT in recognition of its critical role in addressing some of the world's most pressing current ...

Dr Villoo Morawala Patell, founder of Avesthagen and Avestagenome Project International, discusses how India can turn its ...

I see the risk-reward as favorable, with a strong balance sheet, upgraded guidance, and multiple expansion potential driven by new product commercialization. NovoCure describes their mission as ...

Raising funding, assembling the initial team, building lab operations from the ground up, generating proof-of-concept ...

Meet Zach Frankel, the secretive investor behind Cognition, Ramp• Why techies are hoarding AI compute in their homes• Plus, Recommendations—our weekly pop culture picks: “Bram Stoker’s Dracula,” “The ...

The business provides AI-enabled data intelligence and decision-support tools for R&D and commercialization to the ...

Vir Biotechnology (NASDAQ:VIR) advances dual-masked T-cell engagers and hepatitis programs as a busy clinical calendar draws attention.

OMass Therapeutics, an Oxford spin-out built on native mass spectrometry, has raised £230 million (about $310 million) in a Series C that CEO ...

For millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented ...

This is a story from a little while ago. I applied for the IPO lottery. An IPO is when a company lists its shares on the stock market for the first time.akippa: Failed to win. Skyfall: Failed to ...